Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Other
Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA
April 2, 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923565
Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923565.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, et al. Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.
Ma, Jianhui, et al. Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2 Apr. 2026. Crossref, doi:10.1158/1535-7163.31923565.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.